DDInter125 DDInter1180
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Asenapine {u} (Compound) binds {v} (Gene) HRH2
Asenapine {u} (Compound) downregulates {v} (Gene) IGFBP2
Asenapine {u} (Compound) causes {v} (Side Effect) Parkinsonism
Asenapine (Compound) resembles Loxapine (Compound)
Asenapine (Compound) binds HRH2 (Gene)
Asenapine (Compound) downregulates IGFBP2 (Gene)
Asenapine (Compound) causes Parkinsonism (Side Effect)